• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Elutia Announces $15.0 Million Registered Direct Offering

    2/3/25 6:30:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELUT alert in real time by email

    SILVER SPRING, Md., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company") today announced it has entered into a definitive agreement with investors for the purchase and sale of 5,520,000 shares of the Company's Class A common stock at a purchase price of $2.50 per share and 480,000 prefunded warrants to purchase up to 480,000 shares of the Company's Class A common stock at a purchase price of $2.499 per prefunded warrant in a registered direct offering. The prefunded warrants are immediately exercisable at an exercise price of $0.001 per each prefunded warrant. The gross proceeds to Elutia from the offering are expected to be approximately $15.0 million, before deducting placement agent fees and other offering expenses payable by Elutia. The offering is expected to close on or about February 4, 2025, subject to customary closing conditions.

    Lake Street Capital Markets is acting as the exclusive placement agent for the offering.

    Elutia intends to use the proceeds from the proposed offering for working capital and other general corporate purposes.

    The securities are being offered and sold by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-267197) previously filed with the U.S. Securities and Exchange Commission (the "SEC") and declared effective by the SEC on September 8, 2022. The offering of such securities is being made only by means of a prospectus supplement that forms a part of the registration statement. Copies of the prospectus supplement and accompanying base prospectus will be filed with the SEC and will be available free of charge on the SEC's website at http://sec.gov. Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained, when available, from Lake Street Capital Markets, LLC at 920 Second Avenue South, Unit 700, Minneapolis, MN 55402, or e-mail at [email protected].

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    Forward-Looking Statements

    This press release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the completion of the Company's offering and the anticipated use of proceeds therefrom. These statements are based on the Company's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements here due to changes in economic, business, competitive or regulatory factors, and other risks and uncertainties, including those set forth in the Company's filings with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. The Company does not undertake any obligation to update or revise these forward-looking statements for any reason, except as required by law.

    Contact:

    Elutia, Inc.

    [email protected]



    Primary Logo

    Get the next $ELUT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELUT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELUT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method

      SILVER SPRING, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a peer-reviewed article describing the first validated method for measuring antibiotic release from a biologic envelope. The novel method demonstrates in vitro elution that closely replicates preclinical studies, offering an approach to characterize drug release while enabling faster, lower cost development and testing of the EluPro portfolio. The article appears in the current issue of Dissolution Technologies. Drug release testing is a critical element of product development and regulatory evaluat

      5/28/25 8:00:00 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales

      - New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m. PT - SILVER SPRING, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today reported strong first-quarter results for 2025 and highlighted key developments driving the adoption of EluPro™. In its first quarter post-launch, EluPro demonstrated strong momentum, establishing its position as a groundbreaking solution for cardiac implantable electronic device (CIED) procedures. Business Highlights: The EluPro™ Revolution is Now Underway: In its first full quarter post-launch, EluPro e

      5/8/25 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

      Move expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today announced it is reclaiming U.S. sales and distribution responsibilities for its cardiovascular portfolio—including ProxiCor®, VasCure®, and Tyke®—following the conclusion of its distribution agreement with LeMaitre Vascular, Inc. The move allows Elutia to directly capture top-line revenue and should improve the gross margin and profitability of this product segment. Elutia has appointed Dwayne Montgomery as Head of Cardiovascular to lead this newly establish

      5/1/25 4:05:06 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Jordan Maybelle

      4 - ELUTIA INC. (0001708527) (Issuer)

      6/2/25 5:00:14 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Zuga Matt

      4 - ELUTIA INC. (0001708527) (Issuer)

      6/2/25 5:00:12 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Rakin Kevin

      4 - ELUTIA INC. (0001708527) (Issuer)

      6/2/25 5:00:14 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Leadership Updates

    Live Leadership Updates

    See more

    $ELUT
    SEC Filings

    See more

    $ELUT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

      SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries. "We are pleased to welcome Ryan to the Elutia CRU as our new Vice President of Operations," said Dr. Randy Mills, Elutia's Chief Executive Officer. "At Elutia, culture matters, and Ryan has both the experience and character to make him an excellent fit and an effectiv

      7/31/24 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ELUTIA INC. (0001708527) (Filer)

      6/4/25 5:00:15 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Elutia Inc.

      SCHEDULE 13G/A - ELUTIA INC. (0001708527) (Subject)

      5/15/25 4:49:05 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Elutia Inc.

      SCHEDULE 13G - ELUTIA INC. (0001708527) (Subject)

      5/15/25 4:25:26 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:30:13 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:28:27 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Birchview Capital, Lp bought $206,958 worth of shares (140,000 units at $1.48) (SEC Form 4) (Amendment)

      4/A - ELUTIA INC. (0001708527) (Issuer)

      2/20/24 12:27:11 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Financials

    Live finance-specific insights

    See more
    • Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

      SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13753035 Please log in approximately 10 minutes prior to the scheduled start time. A liv

      5/1/25 8:00:00 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

      SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13751810 Please log in approximately 10 minutes prior to the scheduled

      2/20/25 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

      Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025 SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2024. Business Highlights: First Commercial Use: Announced the first patient implant of EluPro, the FDA-cleared antibiotic-eluting biologic envelope for pacemakers and neurostimulators.Strong Initial Adoption: EluPro is being utilized across all major cardiac implantable electronic device (CIED) brands and in neurostimulation procedures. EluPro now accounts

      11/14/24 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Elutia Inc.

      SC 13G - ELUTIA INC. (0001708527) (Subject)

      10/15/24 6:59:31 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Elutia Inc. (Amendment)

      SC 13G/A - ELUTIA INC. (0001708527) (Subject)

      2/20/24 12:03:03 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care